Completed inclusion of patients in the phase I/II extension study of Amphinex®

Posted on May 30, 2012

Oslo, 29 May 2012 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has completed inclusion of patients in the phase I/II extension study of Amphinex® in combination with the cytotoxic agent bleomycin. The objective of the study was to investigate doses below the levels used in the phase I/II study that […]

Status of the phase II study of Amphinex® in head and neck cancer patients

Posted on Mar 30, 2012

Oslo, 29 March 2012 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today status for the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients. All preparations necessary to include patients are completed. The National Center for Tumor Diseases (NCT), University Hospital Heidelberg, and Ludwig […]

Received CE marking for the PCI 652nm medical laser

Posted on Jan 13, 2012

Oslo, 2 January 2012 – PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has received CE marking for its PCI 652nm laser as a medical device. PCI Biotech is approved as manufacturer and distributor of the laser. The approvals have been issued by the notifying body NEMKO, Norway. The PCI 652nm laser […]